Transaction DateRecipientSharesTypePriceValue
25th November 2020Capital, Llc Armistice15,000Open or private purchase$2.39$35,850.00
25th November 2020Capital, Llc Armistice0Open or private purchase$0.00
24th November 2020Capital, Llc Armistice0Open or private purchase$0.00
24th November 2020Capital, Llc Armistice47,733Open or private purchase$2.40$114,559.20
23rd November 2020Capital, Llc Armistice0Open or private purchase$0.00
23rd November 2020Capital, Llc Armistice37,267Open or private purchase$2.32$86,459.44
16th November 2020Anne M. Phillips18,949Sale back to the issuer$0.00
16th November 2020James R Sulat35,090Sale back to the issuer$0.00
16th November 2020Paul R. Fonteyne14,676Sale back to the issuer$0.00
16th November 2020Davey Scoon43,898Sale back to the issuer$0.00
Amag Pharmaceuticals
Amag Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.


AMAG Pharmaceuticals, Inc. focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.


Ticker: AMAG
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 792977
Employees: 440
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $99 M (-12%)
Inventory, Net: $30 M (0%)
Assets, Current: $264 M (-16%)
Property, Plant and Equipment, Net: $3 M (0%)
Assets: $716 M (-9%)
Accounts Payable, Current: $13 M (-52%)
Accrued Liabilities, Current: $145 M (0%)
Liabilities, Current: $161 M (-24%)
Long-term Debt, Excluding Current Maturities: $285 M (2%)
Other Liabilities, Noncurrent: $828 Th (830%)
Liabilities: $466 M (-8%)
Common Stock, Value, Issued: $344 Th (1%)
Common Stock, Shares, Issued: $34 M (1%)
Additional Paid in Capital, Common Stock: $1 B (0%)
Retained Earnings (Accumulated Deficit): $1 B (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $3 M (-8%)
Stockholders' Equity (Parent): $249 M (0%)
Liabilities and Equity: $716 M (-9%)
Revenue: $53 M (-57%)
Cost of Revenue: $18 M (-57%)
Restructuring Charges: $8 M (0%)
Operating Income/Loss: $7 M (-71%)
Other Income, net: $6 M (-42%)
Provision for income taxes: $160 Th (0%)